← Back to Clinical Trials
Recruiting NCT06690970

NCT06690970 Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06690970
Status Recruiting
Phase
Sponsor Tianjin Medical University
Condition PSMA-related Disease
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2020-09-01
Primary Completion 2027-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
68Ga/18F-PSMA/PSFA

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2020-09-01 with a primary completion date of 2027-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.

Eligibility Criteria

Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Contact & Investigator

Central Contact

Haonan Yu, MD

✉ dreamadam@126.com

📞 +8613821000597

Frequently Asked Questions

Who can join the NCT06690970 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying PSMA-related Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06690970 currently recruiting?

Yes, NCT06690970 is actively recruiting participants. Contact the research team at dreamadam@126.com for enrollment information.

Where is the NCT06690970 trial being conducted?

This trial is being conducted at Hefei, China, Tianjin, China.

Who is sponsoring the NCT06690970 clinical trial?

NCT06690970 is sponsored by Tianjin Medical University. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology